Omadacycline is an antibiotic from the tetracycline class of antibiotics. It is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is the first in a new class of antibiotics called aminomethylcyclines, which are derived from the tetracyclines and contain a novel aminomethyl functional group. Omadacycline has a novel mechanism of action that prevents bacteria from forming or repairing their cell walls, resulting in the death of the bacteria. It also has a broad spectrum of activity, meaning it is effective against a wide range of bacteria. In addition, omadacycline is highly stable in the presence of human enzymes that can break down other antibiotics, making it less likely to be affected by resistance.
Omadacycline, sold under the brand name Nuzyra, is a prescription antibiotic medication belonging to the aminomethylcycline subclass of tetracyclines. Here's a breakdown of its key aspects:
Type of drug: Antibiotic
Brand name: Nuzyra
Applications:
- Treats community-acquired bacterial pneumonia (CABP) in adults. This refers to a lung infection caused by bacteria acquired outside of a hospital setting.
- Treats acute bacterial skin and skin structure infections (ABSSSI) in adults. These are severe skin infections encompassing various layers.
Properties:
- Broad-spectrum antibiotic: Omadacycline is effective against a wide range of bacteria, including some strains resistant to other antibiotics.
- Mechanism of action: It disrupts protein synthesis in bacteria, hindering their growth and reproduction.
Important points to remember:
- Omadacycline is only available with a prescription from a qualified healthcare professional.
- Self-administration is not recommended due to potential risks and the need for proper diagnosis to ensure it's the appropriate medication for the specific infection.